ALZUMAb, Indian Psoriasis Drug

• The first instance of a breakthrough innovation from India with a potential to treat multiple autoimmune diseases.
• Biocon’s ALZUMAb™ (Itolizumab) is the first anti-CD6 monoclonal antibody to be commercialized, an outcome of path breaking research in India. This new line of treatment will usher in a paradigm shift in the management of psoriasis.
• What makes this drug so special is that it is an antibody that targets a surface marker on T cells! The drug targets the CD6 surface receptor, binding to it and blocking activation of T cells in inflammatory environments within the body. The surface receptor, CD6, is also important for T-cell migration to sites of inflammation and maturation to become pro-inflammatory. 
•  Reference: http://www.medicaldaily.com/alzumab-indian-psoriasis-drug-first-biologic-med-its-kind-when-will-it-hit-us-market-250987